Abstract

ObjectivesTo explore posttranslational modifications (PTMs), including proteolytic activation, multimerization, complex formation and citrullination of gelatinases, in particular of gelatinase B/MMP-9, and to detect in gelatin-Sepharose affinity-purified synovial fluids, the presence of specific MMP proteoforms in relation to arthritis.MethodsLatent, activated, complexed and truncated gelatinase-A/MMP-2 and gelatinase B/MMP-9 proteoforms were detected with the use of zymography analysis to compare specific levels, with substrate conversion assays, to test net proteolytic activities and by Western blot analysis to decipher truncation variants. Citrullination was detected with enhanced sensitivity, by the use of a new monoclonal antibody against modified citrullines.ResultsAll MMP-9 and MMP-2 proteoforms were identified in archival synovial fluids with the use of zymography analysis and the levels of MMP-9 versus MMP-2 were studied in various arthritic diseases, including rheumatoid arthritis (RA). Secondly, we resolved misinterpretations of MMP-9 levels versus proteolytic activities. Thirdly, a citrullinated, truncated proteoform of MMP-9 was discovered in archival RA synovial fluid samples and its presence was corroborated as citrullinated hemopexin-less MMP-9 in a small prospective RA sample cohort.ConclusionSynovial fluids from rheumatoid arthritis contain high levels of MMP-9, including its truncated and citrullinated proteoform. The combination of MMP-9 as analyte and its PTM by citrullination could be of clinical interest, especially in the field of arthritic diseases.

Highlights

  • Rheumatology research has witnessed leaps of progress by the combination of basic and clinical research

  • Heterodimer detection may be used as a surrogate biomarker for the presence and activated state of neutrophils [31]

  • Via the anti-modified citrulline (AMC)-method with our antibody N1B8, we identified citrullinated MMP-9 proteoforms at 57 kDa and 25 kDa on Western Blot (Figure 3D, red arrowheads b and c)

Read more

Summary

Introduction

Rheumatology research has witnessed leaps of progress by the combination of basic and clinical research. This resulted in the therapeutic blockade of tumour necrosis factor (TNF) signalling in RA. This breakthrough anticipated and came without sophisticated high-end single cell RNA-sequencing analysis [1]. The discovery of antibodies against citrullinated peptides in RA was another breakthrough. Citrulline is an essential constituent of antigenic determinants for RA-specific autoantibodies [2]. The detection of circulating antibody titers against citrullinated (cyclic) peptides (CCP), e.g. anti-citrullinated peptide antibodies (ACPA) is used today for differential diagnosis, therapeutic follow-up and prognosis of patients with various forms of arthritis [3, 4]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call